Core Insights - The company, Juzhi Biotechnology, has received approval for its recombinant type I α1 collagen protein lyophilized fiber, which is indicated for facial dermal tissue filling to correct dynamic wrinkles such as glabellar lines, forehead lines, and crow's feet [1][2]. Product Development - Juzhi Biotechnology has four recombinant collagen injection products under application, including liquid and solid formulations for facial wrinkles and gels for nasolabial folds and neck wrinkles [1]. - The company’s recombinant collagen gel for neck wrinkles has entered the priority approval channel, which is expected to expedite the approval process for its products [2]. Innovation and Patents - The company has received patent authorization for two innovative products: a recombinant type IV collagen composition for sensitive skin care and a fermented ginseng product aimed at cognitive impairment and memory improvement [2]. Financial Projections - Juzhi Biotechnology is a leader in the recombinant collagen sector in China, with projected net profits of 2.566 billion, 3.214 billion, and 4.046 billion yuan for 2025-2027, reflecting year-on-year growth rates of 24%, 25%, and 26% respectively [3]. - The latest closing price corresponds to a price-to-earnings ratio of 16, 12, and 10 for 2025-2027, maintaining a "buy" rating [3].
巨子生物(2367.HK)点评：首款Ⅰ型重组胶原三类械获批 打开医美成长新曲线